jueves, 2 de junio de 2016
Cancer Currents Blog: FDA Approves First Immunotherapy for Lymphoma
FDA Approves First Immunotherapy for Lymphoma - National Cancer Institute
The U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo®) on May 17 for the treatment of some patients with classical Hodgkin lymphoma (cHL). The approval is for the treatment of patients whose disease has relapsed or worsened after they received anautologous hematopoietic stem cell transplantation (HSCT) followed by brentuximab vedotin(Adcetris®). Nivolumab—which has already been approved for the treatment of metastatic melanoma, lung cancer, and kidney cancer—is the first immunotherapy agent approved for any type of lymphoma.